Antibody-mediated rejection after lung transplantation

Area of Science:

• Immunology
• Transplantation Medicine
• Pulmonology

Background:

• Antibody-mediated rejection (AMR) is a significant cause of acute allograft dysfunction in lung transplantation.
• Established diagnostic criteria for AMR have limitations, impacting uniform definition and treatment.
• Existing treatment strategies for AMR are often adapted from other fields with limited efficacy data.

Purpose of the Study:

• To review the history, mechanisms, diagnosis, and treatment of AMR in lung transplantation.
• To highlight current limitations in AMR diagnosis and treatment effectiveness.
• To identify knowledge gaps and future research directions for improving AMR outcomes.

Main Methods:

• Literature review of AMR in lung transplantation.
• Analysis of current diagnostic criteria and treatment modalities.
• Discussion of long-term outcomes, including chronic lung allograft dysfunction (CLAD).

Main Results:

• AMR is frequently refractory to current therapies, leading to graft failure and death.
• AMR is associated with increased rates of CLAD and poorer long-term survival.
• Significant gaps exist in understanding AMR epidemiology, mechanisms, diagnosis, and treatment.

Conclusions:

• Further research is crucial to define chronic and subclinical AMR.
• Head-to-head comparisons of treatment protocols are needed to establish optimal approaches.
• Development of novel diagnostic techniques for early AMR detection and treatment is essential.